Tirzepatide in PWS, HO and GNSO

NCT06901245 on ClinicalTrials.gov · last registry update 2025-09-16

A small phase 4 — 36 participants, against a typical 75. Its estimated completion date, June 2026, has passed with no update to the record. Primary outcome, as filed: Change in weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Grace Kim
Sponsor type: Other
Enrollment: 36
Started: 2025-05-01
Primary completion: 2026-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in weight

Conditions studied

Prader-Willi Syndrome · Hypothalamic Obesity · Obesity/Therapy

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.